Acne Vulgaris: Management
In development [GID-NG10109] Expected publication date: 09 June 2021
Search results
719 results
-
-
Mental health community settings
In development [GID-SGWAVE0702] Expected publication date: TBC
-
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Proposed [GID-TA10723] Expected publication date: TBC
-
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]
Proposed [GID-TA10726] Expected publication date: TBC
-
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Proposed [GID-TA10431] Expected publication date: TBC
-
Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma [ID1625]
In development [GID-TA10643] Expected publication date: 16 June 2021
-
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
In development [GID-TA10667] Expected publication date: TBC
-
Vaccine uptake in the general population
In development [GID-NG10139] Expected publication date: 06 April 2022
-
Integrated health and social care for people experiencing homelessness
In development [GID-NG10170] Expected publication date: 16 March 2022
-
Pelvic floor dysfunction: prevention and non-surgical management
In development [GID-NG10123] Expected publication date: 09 December 2021
-
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]
In development [GID-TA10646] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
In development [GID-TA10405] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]
In development [GID-TA10531] Expected publication date: 15 December 2021
-
Dapagliflozin for treating chronic kidney disease [ID3866]
Proposed [GID-TA10808] Expected publication date: TBC
-
Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]
Proposed [GID-TA10738] Expected publication date: TBC
-
Ofatumumab for treating relapsing multiple sclerosis [ID1677]
In development [GID-TA10557] Expected publication date: TBC
-
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]
In development [GID-TA10584] Expected publication date: 05 May 2021
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]
In development [GID-TA10582] Expected publication date: 19 May 2021
-
Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]
In development [GID-TA10526] Expected publication date: TBC
-
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]
In development [GID-TA10449] Expected publication date: TBC
-
Fenfluramine for treating Dravet syndrome [ID1109]
In development [GID-TA10373] Expected publication date: 26 May 2021
-
Epilepsies in children, young people and adults
In development [GID-NG10112] Expected publication date: 09 March 2022
-
Intrapartum care for healthy women and babies (update)
In development [GID-NG10174] Expected publication date: 22 March 2023
-
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
Proposed [GID-TA10733] Expected publication date: TBC
-
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies [ID3805]
In development [GID-TA10671] Expected publication date: TBC
-
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development [GID-TA10592] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
In development [GID-TA10596] Expected publication date: 15 December 2021
-
Shared decision making
In development [GID-NG10120] Expected publication date: 17 June 2021
-
Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]
In development [GID-TA10534] Expected publication date: TBC
-
Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]
In development [GID-TA10524] Expected publication date: TBC
-
Head injury: assessment and early management
In development [GID-NG10164] Expected publication date: 11 May 2022
-
Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]
In development [GID-TA10697] Expected publication date: TBC
-
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]
In development [GID-TA10466] Expected publication date: 28 April 2021
-
Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]
In development [GID-TA10564] Expected publication date: TBC
-
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]
Proposed [GID-TA10722] Expected publication date: TBC
-
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
In development [GID-TA10363] Expected publication date: TBC
-
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
In development [GID-TA10609] Expected publication date: TBC
-
Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940
In development [GID-TA10397] Expected publication date: TBC
-
Pelareorep for untreated pancreatic cancer [ID1074]
In development [GID-TA10689] Expected publication date: TBC
-
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]
Proposed [GID-TA10662] Expected publication date: TBC
-
Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]
In development [GID-TA10686] Expected publication date: TBC
-
Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]
In development [GID-TA10687] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]
Proposed [GID-TA10707] Expected publication date: TBC
-
Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]
Proposed [GID-TA10709] Expected publication date: TBC
-
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
In development [GID-TA10427] Expected publication date: TBC
-
Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)
In development [GID-TA10435] Expected publication date: TBC
-
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Proposed [GID-TA10748] Expected publication date: TBC
-
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]
Proposed [GID-TA10750] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852 ]
Proposed [GID-TA10751] Expected publication date: TBC
-
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
Proposed [GID-TA10752] Expected publication date: TBC